Semafore Pharmaceuticals, Inc.
8496 Georgetown Road
Indianapolis
Indiana
46268
United States
Tel: 317-876-3075
Fax: 317-872-1379
Website: http://www.semaforepharma.com/
About Semafore Pharmaceuticals, Inc.
Founded in 2000, Semafore is a small molecule drug discovery and development company that is targeting the PI3 kinase (PI3K) and PTEN cell signaling pathway to create a portfolio of innovative oncology products expected to have significant benefits over existing and developmental therapies. Increasing recognition of the central role of PI3K/PTEN in regulating cell life and death is making this pathway a prime target for drug discovery and development related to oncology, immunology and other diseases. Semafore is in pre-IND stages of drug development with a clinical candidate in its small molecule PI3K program, SF1126, expecting to enter clinical trials in late 2005 in prostate, breast, and brain cancer - cancers heavily dependent on PI3K. The company is also developing small molecule PTEN inhibitors, which have potential application in cancer and in diseases where safeguarding cell survival is crucial, including protection of the bone marrow during chemotherapy and to protect the heart from ischemia and reperfusion injury. early preclinical development in the PTEN program. Semafore has ambitious scientific and business development programs well underway. Semafore is developing a leadership position in PI3K/PTEN pathway expertise, discovery platforms, and drug products, and is assembling the core people required to discover and develop the next generation of cancer therapies.Semafore's lead products are expected to have significant efficacy advantages compared to existing and developmental cancer therapies. For more information, see the company's Web site www.semaforepharma.com.
Last Updated: 03-28-05
30 articles about Semafore Pharmaceuticals, Inc.
-
BioSpace is proud to present its NextGen “Class of 2017,” which is a list of 20 up-and-coming life science companies that launched no earlier than 2014.
-
Semafore Pharmaceuticals, Inc. to Present SF1126 Clinical Data at American Society of Clinical Oncology Annual Meeting
5/26/2011
-
Semafore Pharmaceuticals, Inc. Reports New Preclinical Data for Multi-Kinase, PI3K/mTOR Inhibitor SF1126 at American Association for Cancer Research
4/5/2011
-
Semafore Pharmaceuticals, Inc. Announces Presentation Highlighting Activity of Multi-Kinase, PI3K/mTOR Inhibitor SF1126 at 2011 American Association for Cancer Research Annual Meeting
3/9/2011
-
Semafore Pharmaceuticals, Inc. Receives FDA Orphan Drug Designation for SF1126 in the Treatment of Chronic Lymphocytic Leukemia
11/9/2010
-
Semafore Pharmaceuticals, Inc. Announces Issuance of U.S. Patent Covering Method of Use for PI3K Inhibitors
6/29/2010
-
Semafore Pharmaceuticals, Inc. Presents New Clinical Data on Novel Prodrug Dual PI3K-mTOR Inhibitor in B-Cell Malignancies and Solid Tumors
6/21/2010
-
Semafore Pharmaceuticals, Inc. Announces Issuance of Key U.S. Patent Covering Composition of Matter for Novel PI3K/mTOR Pathway Inhibitor
2/22/2010
-
Semafore Pharmaceuticals, Inc. Reports Encouraging Phase I Data at American Society of Hematology for Novel PI3K/mTOR Pathway Inhibitor
12/8/2009
-
Semafore Pharmaceuticals, Inc. Announces Phase I Data Presentation Highlighting Novel PI3K Pathway Inhibitor at 51st American Society of Hematology Annual Meeting
11/16/2009
-
Semafore Pharmaceuticals, Inc. Retains Management Consulting Firm; Names Principal to Key Management Position
9/21/2009
-
Clinical Data on Semafore Pharmaceuticals, Inc.'s SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, to be Presented at the 2009 American Society of Clinical Oncology Meeting
5/20/2009
-
Semafore Pharmaceuticals, Inc. Achieves a Preclinical Milestone with SF2626, a PI3K-MEK Dual Pathway Kinase Inhibitor
3/17/2009
-
SF1126, Semafore Pharmaceuticals, Inc.'s PI3 Kinase Inhibitor, Found to Block Angiogenic Signaling From Both VEGF and Bv8 in Multiple Cell Line
8/27/2008
-
Semafore Pharmaceuticals, Inc. Broadens Pipeline With Multi-Targeted Kinase Inhibitors
8/27/2008
-
Semafore Pharmaceuticals, Inc. Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors
6/4/2008
-
Semafore Pharmaceuticals, Inc.'s PI3 Kinase Inhibitor SF1126 is a Vascular Targeted Conjugate in Phase I Clinical Trials in Solid Tumors and Multiple Myeloma
4/14/2008
-
Semafore Pharmaceuticals, Inc.'s SF1126 Exhibits Antitumor and Antiangiogenic Activity
1/9/2008
-
Semafore Pharmaceuticals, Inc. and Multiple Myeloma Research Foundation (MMRF) Dose First Patient in Phase I Study of Targeted PI3 Kinase (PI3K) Inhibitor
1/7/2008
-
Semafore Pharmaceuticals, Inc.'s PI3 Kinase Inhibitor SF1126 is Active Against Tumor and Tumor Cells and Synergizes with Standard Chemotherapy Agents
10/26/2007